SCLPScancell HoldingsSCLP info
$0.19info-1.67%24h
Global rank
Market cap$173.48M
Change 7d-11.94%
YTD Performance37.21%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Scancell Holdings (SCLP) Stock Overview

    Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, ovarian, renal, and head and neck cancers; and Modi-2, which targets homocitrullinated cancer antigens. In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

    SCLP Stock Information

    Symbol
    SCLP
    Address
    Bellhouse BuildingOxford, OX4 4GDUnited Kingdom
    Founded
    -
    Trading hours
    8:00 AM - 4:30 PM GMT
    Website
    https://www.scancell.co.uk
    Country
    πŸ‡¬πŸ‡§ United Kingdom
    Phone Number
    44 18 6558 2066

    Scancell Holdings (SCLP) Price Chart

    -
    Value:-

    Scancell Holdings Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.18698104836153895
    N/A
    Market Cap
    $173.48M
    N/A
    Shares Outstanding
    927.82M
    N/A
    Employees
    51.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org